have not previously been treated with any hormonal therapy. In the FALCON study, eligible patients will be randomised 1:1 to receive either fulvestrant (500 mg/day intramuscular injection) on days 0, ...
Dr Reddy's Laboratories Ltd. announced the launch of the US Food and Drug Administration (FDA) approved fulvestrant injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic equivalent ...
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results